An update on the topical and oral therapy options for treating pediatric atopic dermatitis
Autor: | Katherine M Stiff, Megan E. Freeze, Steven R. Feldman, Katelyn R Glines, Lindsay C. Strowd, Abigail Cline |
---|---|
Rok vydání: | 2019 |
Předmět: |
medicine.medical_specialty
Azathioprine Administration Cutaneous Dermatitis Atopic Medication Adherence 03 medical and health sciences 0302 clinical medicine medicine Humans Immunologic Factors Pharmacology (medical) Child Oral therapy Pharmacology Biological Products business.industry Crisaborole General Medicine Atopic dermatitis medicine.disease Dupilumab Dermatology body regions Calcineurin 030220 oncology & carcinogenesis Quality of Life Methotrexate Dermatologic Agents Apremilast business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Expert Opinion on Pharmacotherapy. 20:621-629 |
ISSN: | 1744-7666 1465-6566 |
Popis: | Atopic dermatitis (AD) is one of the most common childhood skin disorders. Multiple mechanisms contribute to the pathology of AD and treatment approaches are directed at these processes.The purpose of this review is to discuss the chemical treatment options for pediatric atopic dermatitis, including immunomodulators and small molecule inhibitors. A systematic literature search was conducted, and publications were reviewed for applicable treatment guidelines.Topical therapy is first-line for pediatric atopic dermatitis. Providers should work closely with patients and caregivers to promote the success of topical treatments. In disease refractory to topical treatments, systemic agents may be considered. Clinical trials are ongoing for the use of biologics in the treatment of pediatric AD. When choosing the most appropriate treatment, physicians should consider the drug efficacy, potential adverse effects, patient adherence, and quality of life for both patients and caregivers. Additional studies are required to determine the safest and most effective doses for systemic therapy in childhood AD. |
Databáze: | OpenAIRE |
Externí odkaz: |